TrialBritish journal of haematology2018

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Natalie Galanina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.